Gastric Bypass In A Pill: New Angles On Diabetes Drug Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Emerging targets are looking at diabetes/obesity crossover, as well as immunometabolic approaches that overlap with dyslipidemia.
You may also be interested in...
Partnering Opportunities In Cardio/Metabolics: “Everybody’s Looking And Nobody’s Got”
Representatives from J&J, GSK, Pfizer and Boehringer Ingelheim discuss their companies’ thinking in terms of cardiovascular/metabolic drug development and business development activity at the TAP conference.
Obesity And Diabetes: Toward A Surgical Solution: An Interview With Francesco Rubino, MD
A new position statement from the International Diabetes Federation that endorses bariatric surgery as a medically indicated therapeutic option for diabetes represents an important philosophical shift for this field, according to Francesco Rubino, MD, chief of gastrointestinal metabolic surgery at Weill Cornell Medical College.
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
The July 19 FDA advisory committee meeting on Bristol-Myers Squibb Co./AstraZeneca PLC's dapagliflozin reflects the hurdles facing type 2 diabetes drug sponsors even when cardiovascular safety concerns are taken out of the picture.